Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WuXi PharmaTech Inks New Pact To Synthesize Compounds For AstraZeneca

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Shanghai-headquartered WuXi PharmaTech, one of China's leading contract research organizations, this week signed a new agreement to synthesize compounds according to AstraZeneca's designs

You may also be interested in...



AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

Venturepharm Rides Chinese Wave Of CRO Growth; Sees Challenges Ahead As Competition Among MNCs, Locals Increase

HONG KONG - The growth of contract research organizations in China has been little short of astounding. China has overtaken India as one of the fastest-growing locations for drug trials, leveraging a huge population and Western-trained doctors into a competitive industry

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC068689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel